Previous Article | Next Article ![]()
Journal of Clinical Microbiology, May 2008, p. 1620-1627, Vol. 46, No. 5
0095-1137/08/$08.00+0 doi:10.1128/JCM.02453-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
,
Centre for Healthcare Associated Infections, Institute of Infection, Immunity and Inflammation, CBS Building, University Park, University of Nottingham, Nottingham NG7 2RD, United Kingdom
Received 20 December 2007/ Returned for modification 29 December 2007/ Accepted 13 February 2008
|
|
|---|
|
|
|---|
Most diagnostic microbiology laboratories continue to identify S. aureus using traditional culture and susceptibility methods that are slow (48 to 72 h) and provide only limited information. Molecular assays based on PCR have been reported for the detection of MRSA (4, 6, 7, 9, 10, 30), the identification of staphylococcal species (17, 20, 21), or the identification of specific virulence genes (5, 11, 14, 15, 18, 19, 22, 24, 26, 33). DNA microarrays can identify, subtype, and detect acquired antibiotic resistance determinants simultaneously (1, 23, 32, 35); however, their clinical value has been limited by a complicated methodology that is unsuitable for routine use in diagnostic microbiology laboratories.
We have developed an oligonucleotide-based microarray (designated VirEp, for virulence and epidemiology microarray) incorporating 84 clinically relevant gene targets for the characterization and molecular typing of clinical isolates of S. aureus in an economical, multiwell format enabling 13 S. aureus isolates to be analyzed simultaneously.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. S. aureus isolates used in this study
|
Slide printing. Oligonucleotides were printed onto amine silane-coated UltraGAPS slides (Corning B.V. Life Sciences) at a concentration of 20 µM in spotting buffer (3 x SSC [1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate], 1.5 M betaine) along with Universal ScoreCard controls (GE Healthcare UK Ltd.) and appropriate positive and negative controls (see the supplemental material). Fourteen replicates of the array were printed on each microarray slide using a QArray Lite robotic arrayer (Genetix Ltd.).
DNA extraction and labeling. Genomic DNA (gDNA) was extracted from S. aureus cultures using the DNeasy tissue kit (Qiagen) according to the manufacturer's instructions with the addition of 5 µl of lysostaphin (0.5 mg/ml) and 2 µl of RNase A (100 mg/ml) to the lysis buffer. The concentration of gDNA was determined using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies Inc.). gDNA and spike-in Universal controls (for details, see Appendix S3 in the supplemental material) were labeled with Cy3-dCTP using a protocol based on that described by Pearson et al. (27).
Hybridization. Microarray slides were incubated in prehybridization solution (5x SSC, 0.1% sodium dodecyl sulfate [SDS], 0.1 mg/ml bovine serum albumin) for 60 min at 60°C, washed twice in 0.1x SSC for 5 min and once in purified water for 30 s at room temperature, and then dried by centrifugation. Prior to hybridization, ProPlate superstructures (Stratech Scientific Ltd.) were attached to the slides to create a multiwell format. Forty picomoles of Cy3-labeled gDNA in 50 µl of hybridization solution (5x SSC, 0.1% SDS, and 0.1 mg/ml herring sperm DNA) was denatured at 95°C for 5 min. Hybridization mixtures were then added to individual wells on the slide before wells were sealed. Slides were hybridized at 60°C for 16 h in the dark with gentle agitation before being washed in 2x SSC-0.1% SDS at 42°C once to remove the superstructure and once for 5 min. Slides were then washed twice for 5 min in 0.1x SSC-0.1% SDS, five times for 1 min in 0.1x SSC, and once for 10 s in 0.01x SSC. Arrays were dried by centrifugation at 1,600 x g for 2 min.
Data analysis.
Hybridized slides were scanned with an Axon 4000B slide scanner (Molecular Devices Corporation) using a resolution of 10 µm, and images were analyzed with GenePix Pro 6.0 software. Spots with a signal-to-noise ratio of
1 and a total median fluorescence at 532 nm of >1,000 after subtraction of the background fluorescence were classified as positive. For a gene target to be considered present, at least two-thirds of the spots corresponding to that gene target had to be positive. Microarray experiments were MIAME (minimum information about a microarray experiment) compliant, and experimental data were deposited in the ArrayExpress repository (2).
PFGE.
S. aureus chromosomal SmaI digests were prepared with the GenePath group 1 reagent kit (Bio-Rad Laboratories), and pulsed-field gel electrophoresis (PFGE) patterns were obtained with a contour-clamped homogeneous electric field apparatus (Bio-Rad) as described previously (13). PFGE images were analyzed with BioNumerics 2.0 software (Applied Maths). Dendrograms were generated using the Dice coefficient and the unweighted-pair group method using average linkages (UPGMA) with 1% tolerance and 0.5% optimization. A similarity cutoff of 80% and a difference of
6 bands were used to define clusters (29, 31). The presence and absence of genes determined by microarray analysis were recorded in a binary format and processed using Bionumerics 2.0 software, and the results were presented as a dendrogram.
Statistical analysis. The reproducibility of microarray data was examined by calculating the coefficient of variation, which is the standard deviation divided by the normalized mean for replicates hybridized to different microarrays. The discriminatory power of the VirEp (virulence and epidemiology) microarray as a typing method was determined by calculating Simpson's index of diversity (8).
|
|
|---|
Application of the VirEp microarray to the identification and characterization of clinical isolates of S. aureus. Labeled DNAs from a collection of 64 clinical isolates of S. aureus were hybridized to the VirEp microarray with the remaining 84 gene targets (Table 1). All isolates were correctly identified as S. aureus based on the presence of cap, coa, cpn60, femA, nuc, and tpi genes. Ten of ten (100%) isolates were correctly identified as MSSA (Table 2), and 30 of 38 (78.9%) isolates were correctly identified as MRSA (Table 2). However, false-negative results for the mecA gene were obtained for eight MRSA isolates from the United Kingdom. Six of the eight isolates were confirmed to possess the mecA gene by PCR. We assume that isolates RSS257 and RSS258, which were mecA negative by PCR, had lost their mec element upon storage at –80°C, which has been reported to be common among MRSA isolates (34). All four CA-MRSA isolates and all three Panton-Valentine leukocidin (PVL)-positive MSSA isolates were correctly identified by the microarray, as were each of six tst-positive MSSA isolates and each of three VRSA isolates tested.
|
View this table: [in a new window] |
TABLE 2. Comparison of laboratory and VirEp microarray characterization for diagnosis of 64 clinical isolates of S. aureus
|
Among the toxin genes, those encoding two exfoliative toxins (eta and etc), alpha-hemolysin (hla), beta-toxin (hlb), delta-toxin (hld), and gamma-hemolysin (hlgA, hlgB, hlgC) were found to be present in almost all of the isolates examined. The leukocidin encoded by lukD and lukE was present in 45.3% of isolates, and PVL, encoded by the lukS and lukF genes, was identified in 10.9% of isolates. Each enterotoxin gene included on the microarray was identified in 6.3% to 67.2% of the isolates examined.
The frequency of antibiotic resistance genes in the isolates studied differed greatly. Genes involved in trimethoprim resistance (dfrA and dfrB), penicillin resistance (fmt), sulfonamide resistance (folP), streptogramin A resistance (lsa, vga), and macrolide resistance (msrA) were identified in all isolates examined. Some antibiotic resistance genes (ereA, ereB, ermC, vat, and vgb) were absent from our study isolates, whereas others (e.g., blaZ) were found in the majority of isolates examined (87.5%). Of the three genes encoding components of multidrug efflux pumps screened, norA was identified in 98.4% of the isolates examined. In contrast, qacA and qacB were found in only 11%, and smr in only <2%, of the isolates. Although we have included a number of acquired antibiotic resistance genes among the gene targets used, we have not attempted at this stage to use them as predictors of antibiotic susceptibility, because considerable further work is required to confirm that the presence of a resistance gene is correlated with phenotypic resistance in S. aureus isolates.
Nine of eleven adhesins included on the microarray were identified in the study isolates. In addition, spa, encoding protein A, was found in 98.4% of isolates, and cna, encoding a collagen adhesin protein, was found in 75% of isolates. All six proteases included on the microarray were present in all study isolates. Of the three gene targets involved in biofilm formation, one (icaA) was present in all isolates, one (aapA) was present in 98.4% of isolates, and one (bap) was absent from the study isolates. The three genes linked to capsular polysaccharide synthesis (cap1A, cap5A, and cap8A) were identified in all the study isolates. The virulence gene regulator sarA was identified in 63 of 64 (98.4%) isolates.
Among the MRSA isolates examined, there were a number of discrepancies with the SCCmec types identified by the VirEp microarray. First, 19 of 38 MRSA isolates failed to hybridize with any of the SCCmec oligonucleotides included on the microarray. Second, for three isolates, oligonucleotides specific for both SCCmec types II and IVc were identified as positive (see Appendix S2 in the supplemental material). Third, five isolates determined to be mecA negative generated positive results for SCCmec type IVc. Finally, isolate MRSA32344, which was identified as possessing SCCmec type I (3), produced a positive result with oligonucleotides specific for SCCmec type IVa. The corresponding pre-MRSA isolate MSSA32130 was correctly identified as mecA negative, but the SCCmec element was not detected.
Analysis of the population structure of clinical S. aureus isolates using PFGE and the VirEp microarray. All replicates of the internal-control S. aureus isolate (NCTC8325) included in the PFGE analysis produced identical restriction fragment profiles clustering at 100% similarity, demonstrating the reproducibility of the method. The 43 test isolates generated 34 PFGE profiles according to the criteria of Tenover et al. (31) and were separated into seven clusters containing 41 out of 43 isolates (Fig. 1). Control isolate NCTC8325 and test isolate NRS265 were the only isolates found to be outliers. Cluster 1 contained 14 isolates (33%) from the United Kingdom, the United States, and France associated with a variety of diseases and included VRSA, MRSA, MSSA, CA-MRSA, and PVL-positive MSSA. Cluster 2 contained two isolates (5%): one from Nottingham, United Kingdom, associated with septic arthritis and one from France linked to endocarditis. Cluster 3 contained seven isolates (16%) from France, Japan, and the United States that were associated with different disease outcomes and included VRSA, glycopeptide-intermediate S. aureus (GISA), and MSSA. Cluster 4 consisted of two isolates (5%), one from France (MRSA) and one from Belgium (GISA). Cluster 5 was also made up of two isolates (5%), one from France and one from Nottingham, both MSSA. Cluster 6 contained eight isolates (19%) from France and the United Kingdom and included two epidemic MRSA-16 (EMRSA-16) isolates, as well as PVL-positive MSSA and MSSA isolates. Cluster 7 contained five EMRSA-15 isolates from the United Kingdom and one PVL-positive MSSA isolate from France.
![]() View larger version (42K): [in a new window] |
FIG. 1. Dendrogram of 43 S. aureus isolates examined by PFGE, produced with Bionumerics (version 2.0) software using the Dice coefficient and UPGMA. Isolates were clustered using the criteria of Tenover et al., where 80% similarity is the cutoff for differentiating closely related isolates (31). Clusters 1 through 7 are shown.
|
![]() View larger version (37K): [in a new window] |
FIG. 2. Dendrogram of 43 clinical S. aureus isolates examined by the VirEp microarray, produced with Bionumerics (version 2.0) software using the Dice coefficient and UPGMA. A cutoff value of 93.5% was used to distinguish genotypes. Genotypes A through E were distinguished.
|
|
View this table: [in a new window] |
TABLE 3. Comparison of PFGE and VirEp microarray results for 18 S. aureus outbreak isolates
|
|
|
|---|
Furthermore, the fact that six of the eight MRSA isolates from the United Kingdom failed to hybridize to the mecA probes on the VirEp microarray yet contained the mecA gene by PCR indicated that the DNA sequences of mecA in the regions corresponding to the three probes are not conserved among all MRSA isolates. This suggests that for some genes, including mecA, sequence variation may be much greater in the wider population than among the few S. aureus isolates that have been sequenced to date. As a consequence, it is clear that further oligonucleotides are required to increase the robustness of mecA detection, a problem that is being encountered with all rapid MRSA detection systems.
The dendrogram generated from the VirEp microarray results illustrates that in general, the grouping of isolates was highly congruent with that observed with PFGE (Fig. 1 and 2). However, all three VRSA isolates were assigned to the same genotype as the EMRSA-15 and -16 isolates (Fig. 1 and 2). It is noteworthy that the percentage of similarity required to differentiate the sequenced S. aureus isolates by using the microarray results is 93.5%, whereas for PFGE it is 80% (31). This indicates that the microarray analysis provides slightly less discrimination than PFGE, probably due to the limited number of gene targets included in the microarray. This was confirmed when values for Simpson's index of diversity were calculated for the VirEp microarray and PFGE (0.771 versus 0.811). Unlike PFGE, however, the microarray provides biologically meaningful data in addition to the typing data. When isolates from two epidemiologically distinct outbreaks were examined by the VirEp microarray and PFGE, only a single incongruent isolate was found. The differences observed with this isolate were due to a difference in gene content (lukD positive, sem negative) (see Appendix S2 in the supplemental material) that could not be detected by PFGE. There were three differences in gene content between genotypes E1 and E2. Genotype E1 lacked the ermA, mupA, and tst genes, whereas genotype E2 possessed these genes (see Appendix S2 in the supplemental material). These data provide evidence that the VirEp microarray may be capable of distinguishing S. aureus isolates from different outbreaks. The VirEp microarray could be refined by the inclusion of additional selected targets that could improve the discriminatory power of the microarray. A recent study has demonstrated the potentially superior resolving power of microarrays compared to PFGE and multilocus sequence typing for typing of CA-MRSA isolates (12).
We anticipate that the VirEp assay could be used after presumptive staphylococci (gram-positive cocci in clusters) have been observed in a positive blood culture and species identification has been confirmed by an alternative methodology, such as a rapid PCR-based assay or fluorescence in situ hybridization with peptide nucleic acid probes (25). The inclusion in the array of oligonucleotides to detect coagulase-negative staphylococci would indicate if the blood culture was a mixture of S. aureus and coagulase-negative staphylococci. Our current development work has been successful in reducing the time taken to perform the VirEp assay to <24 h.
We thank Paddy Tighe, University of Nottingham, for helpful discussions concerning microarray technology and Katrina Levi, Nottingham University Hospitals NHS Trust, for assistance with PFGE and BioNumerics software. Nick Day, Angela Kearns, Sharon Peacock, Donald Morrison, John Corkill, Teruyo Ito, and the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) are thanked for the provision of S. aureus clinical isolates.
All authors declare no conflict of interest.
Published ahead of print on 20 February 2008. ![]()
Supplemental material for this article may be found at http://jcm.asm.org/. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»